Genomed S.A. ended 2025 with unprecedented financial and operational results. The company increased its revenue by 26.6% year-on-year to PLN 29.1 million, achieved a net profit of PLN 3.4 million and improved its net profit margin to 11.7%, with ROE at 24.1%.

Last year, Genomed also recorded a 36% increase in sales of genetic tests and a 67% increase in sales of NGS services in the Life Science segment. This dynamic growth was driven by investments in laboratory automation, next-generation sequencing technologies, bioinformatics and AI solutions, as well as the continued development of the proprietary BroVar platform and diagnostic projects based on genomic data analysis.

Full report